186 related articles for article (PubMed ID: 7575227)
1. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study.
Kälviäinen R; Aikiä M; Saukkonen AM; Mervaala E; Riekkinen PJ
Arch Neurol; 1995 Oct; 52(10):989-96. PubMed ID: 7575227
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and cognitive effects of vigabatrin.
Ylinen A; Kälviäinen R; Riekkinen PJ
Acta Neurol Scand Suppl; 1995; 162():47-50. PubMed ID: 7495191
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group.
Chadwick D
Lancet; 1999 Jul; 354(9172):13-9. PubMed ID: 10406359
[TBL] [Abstract][Full Text] [Related]
4. Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children.
Zamponi N; Cardinali C
Arch Neurol; 1999 May; 56(5):605-7. PubMed ID: 10328256
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of vigabatrin vs. carbamazepine in monotherapy of newly diagnosed partial seizures in children.
Sobaniec W; Kułak W; Strzelecka J; Smigielska-Kuzia J; Boćkowski L
Pharmacol Rep; 2005; 57(5):646-53. PubMed ID: 16227648
[TBL] [Abstract][Full Text] [Related]
6. Vigabatrin and carbamazepine monotherapy for newly diagnosed epilepsy.
Walker MC; Cockerell OC; Sander JW
Arch Neurol; 1996 Jun; 53(6):477-8. PubMed ID: 8660147
[No Abstract] [Full Text] [Related]
7. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study.
Tanganelli P; Regesta G
Epilepsy Res; 1996 Nov; 25(3):257-62. PubMed ID: 8956924
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled pilot study of vigabatrin versus carbamazepine monotherapy in newly diagnosed patients with epilepsy: an interim report.
Kälviäinen R; Aikiä M; Partanen J; Sivenius J; Mumford J; Saksa M; Riekkinen PJ
J Child Neurol; 1991; Suppl 2():S60-9. PubMed ID: 1940126
[TBL] [Abstract][Full Text] [Related]
9. Newer antiepileptic drugs as monotherapy: data on vigabatrin.
Fisher R; Kälviäinen R; Tanganelli P; Regesta G
Neurology; 1996 Jul; 47(1 Suppl 1):S2-5. PubMed ID: 8677032
[TBL] [Abstract][Full Text] [Related]
10. Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy.
Nousiainen I; Kälviäinen R; Mäntyjärvi M
Ophthalmology; 2000 May; 107(5):884-8. PubMed ID: 10811079
[TBL] [Abstract][Full Text] [Related]
11. Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial.
Schmitz B; Dimova S; Zhang Y; Chellun D; De Backer M; Gasalla T
Epilepsy Res; 2020 Jan; 159():106220. PubMed ID: 31812127
[TBL] [Abstract][Full Text] [Related]
12. Plasma concentrations of vigabatrin in epileptic patients.
Sánchez-Alcaraz A; Quintana B; Rodriguez I; López E
J Clin Pharm Ther; 1996 Dec; 21(6):393-8. PubMed ID: 9201565
[TBL] [Abstract][Full Text] [Related]
13. Vigabatrin as first add-on treatment in carbamazepine-resistant epilepsy patients.
Murri L; Iudice A
Acta Neurol Scand Suppl; 1995; 162():40-2. PubMed ID: 7495189
[TBL] [Abstract][Full Text] [Related]
14. [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic].
Vogt H; Krämer G
Schweiz Med Wochenschr; 1995 Jan; 125(4):125-32. PubMed ID: 7878401
[TBL] [Abstract][Full Text] [Related]
15. Behavioural abnormalities and retention rates of anti-epilepsy drugs during long-term treatment of epilepsy: a clinical perspective.
Schmidt D
Acta Neurol Scand Suppl; 1995; 162():7-10. PubMed ID: 7495192
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of vigabatrin associated with carbamazepine in the treatment of epilepsy. Follow up 1993-1996].
De Romanis F; Sopranzi N
Clin Ter; 1998; 149(2):131-4. PubMed ID: 9780478
[TBL] [Abstract][Full Text] [Related]
17. A quantitative study of daytime sleepiness induced by carbamazepine and add-on vigabatrin in epileptic patients.
Bonanni E; Massetani R; Galli R; Gneri C; Petri M; Iudice A; Murri L
Acta Neurol Scand; 1997 Apr; 95(4):193-6. PubMed ID: 9150807
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy.
Ben-Menachem E; Grebe HP; Terada K; Jensen L; Li T; De Backer M; Steiniger-Brach B; Gasalla T; Brock M; Biton V
Epilepsia; 2019 Dec; 60(12):2437-2447. PubMed ID: 31755090
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of first-line vigabatrin monotherapy in childhood partial epilepsies.
Gobbi G; Pini A; Bertani G; Menegati E; Tiberti A; Valseriati D; Besana D; Rasmini P; Guerrini R; Belmonte A; Veggiotti P; Resi C; Lanzi G; Capovilla G; Galeone D; Milani S
Epilepsy Res; 1999 May; 35(1):29-37. PubMed ID: 10232792
[TBL] [Abstract][Full Text] [Related]
20. Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine monotherapies.
Kälviäinen R; Halonen T; Pitkänen A; Riekkinen PJ
J Neurochem; 1993 Apr; 60(4):1244-50. PubMed ID: 8095971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
